These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28648556)

  • 1. NICE recommends routine NHS funding for Kadcyla.
    Venkatesa P
    Lancet Oncol; 2017 Aug; 18(8):e435. PubMed ID: 28648556
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE approves trastuzumab emtansine after deal with drug company.
    Kmietowicz Z
    BMJ; 2017 Jun; 357():j2930. PubMed ID: 28623237
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab emtansine for HER2-positive breast cancer.
    Venkatesan P
    Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment.
    Ruiz-Rivero J; Horcajada-Reales C; Tardío JC; Borbujo-Martínez JM
    An Bras Dermatol; 2018; 93(6):938-939. PubMed ID: 30484553
    [No Abstract]   [Full Text] [Related]  

  • 5. Corneal Changes in Trastuzumab Emtansine Treatment.
    Kreps EO; Derveaux T; Denys H
    Clin Breast Cancer; 2018 Aug; 18(4):e427-e429. PubMed ID: 29615304
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE confirms advanced breast cancer drug is too expensive for NHS.
    White C
    BMJ; 2014 Aug; 349():g5078. PubMed ID: 25106642
    [No Abstract]   [Full Text] [Related]  

  • 9. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab-emtansine might affect the survival outcome by reversing increased platelet-to-lymphocyte ratio in HER2-positive metastatic breast cancer patients.
    Altundag K
    J BUON; 2019; 24(1):407. PubMed ID: 30942001
    [No Abstract]   [Full Text] [Related]  

  • 11. Interstitial pneumonitis associated with trastuzumab emtansine.
    Alkan A
    J Oncol Pharm Pract; 2019 Oct; 25(7):1798-1800. PubMed ID: 30426834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine and cost-based decision making.
    The Lancet
    Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on antibody-drug conjugates in breast cancer.
    Hugo HS
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):148-151. PubMed ID: 33739962
    [No Abstract]   [Full Text] [Related]  

  • 14. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE rejects trastuzumab emtansine for use on NHS.
    Kmietowicz Z
    BMJ; 2015 Dec; 351():h6837. PubMed ID: 26673454
    [No Abstract]   [Full Text] [Related]  

  • 16. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
    Diaby V; Ali AA; Williams KJ; Ezendu K; Soto-Perez-de-Celis E; Chavarri-Guerra Y; de Lima Lopes G
    Breast Cancer Res Treat; 2017 Dec; 166(3):951-963. PubMed ID: 28840424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Hall CJ; Umeweni N; Knight H; Smith L
    Lancet Oncol; 2016 Oct; 17(10):1357-1358. PubMed ID: 27567055
    [No Abstract]   [Full Text] [Related]  

  • 20. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
    Olsen J; Jensen KF; Olesen DS; Knoop A
    J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.